Emergent Biosolutions (EBS) Scheduled to Post Earnings on Wednesday

Emergent Biosolutions (NYSE:EBS) will be announcing its earnings results after the market closes on Wednesday, February 21st. Analysts expect the company to announce earnings of $0.64 per share for the quarter.

Shares of Emergent Biosolutions (EBS) opened at $47.20 on Wednesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.37 and a quick ratio of 6.46. The firm has a market capitalization of $2,320.00, a price-to-earnings ratio of 29.50, a PEG ratio of 0.95 and a beta of 1.32. Emergent Biosolutions has a 52-week low of $27.94 and a 52-week high of $51.25.

A number of analysts have recently weighed in on EBS shares. Zacks Investment Research cut Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 19th. Goldman Sachs Group started coverage on Emergent Biosolutions in a research report on Wednesday, January 24th. They issued a “neutral” rating and a $55.00 price objective for the company. Finally, Chardan Capital raised their price objective on Emergent Biosolutions from $47.00 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $51.00.

In related news, Chairman Fuad El-Hibri sold 47,983 shares of the firm’s stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $41.88, for a total value of $2,009,528.04. Following the completion of the transaction, the chairman now owns 1,550,216 shares in the company, valued at approximately $64,923,046.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronald Richard sold 23,681 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $45.02, for a total value of $1,066,118.62. Following the completion of the transaction, the director now owns 47,091 shares of the company’s stock, valued at approximately $2,120,036.82. The disclosure for this sale can be found here. Insiders sold a total of 125,722 shares of company stock valued at $5,604,541 in the last three months. Insiders own 16.50% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/14/emergent-biosolutions-ebs-scheduled-to-post-earnings-on-wednesday.html.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Earnings History for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply